Safety and Effectiveness of the Drug DPC 083 in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Patients Who Are Failing Treatment With Nonnucleoside Reverse Transcriptase Inhibitors

NCT ID: NCT00007449

Last Updated: 2005-06-24

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL

Brief Summary

The purpose of this study is to determine the safety and tolerability of the study drug DPC 083 combined with 2 nucleoside reverse transcriptase inhibitors (NRTIs) in HIV-infected patients who are failing their nonnucleoside reverse transcriptase inhibitor (NNRTI) treatment.

In some studies DPC 083 (an NNRTI) has been found to lower the amount of HIV in the blood (viral load), where drug-resistant types of HIV were not lowered by other NNRTIs. This study will attempt to determine how safe DPC 083 is when it is taken in combination with 2 NRTIs.

Detailed Description

Preclinical and human pharmacokinetic data suggest that DPC 083 can be administered once daily and provide trough plasma concentrations of free drug that will suppress replication of HIV-1, including strains containing key resistance mutations observed after failure of treatment with currently available NNRTIs. This study will provide an assessment of safety and a preliminary assessment of the efficacy of DPC 083 when administered at a dose of 100 mg once daily in combination with 2 NRTIs, in a population of HIV-1-infected patients who are failing treatment with an NNRTI-containing regimen.

Patients receive DPC 083 once daily in combination with 2 NRTIs. The 2 NRTIs are selected by the investigators, based on HIV-1 genotyping results. Analyses for patient safety and drug efficacy are done at Weeks 8, 24, and 48 using results from clinical laboratory tests and physical exams. Patients continue to receive DPC 083 and NRTIs until the last patient enrolled in the study completes 48 weeks of treatment. Patients return for post-therapy follow-up visits at 1 and 3 months following early termination or study completion. Some patients may participate in a substudy which evaluates changes in HIV-1 levels in cerebrospinal fluid (CSF).

Conditions

HIV Infections

Keywords

HIV-1; Drug Therapy, Combination; RNA, Viral; Reverse Transcriptase Inhibitors; Anti-HIV Agents; Viral Load

Study Design

• Primary Study Purpose: TREATMENT

Interventions

DPC 083

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Have HIV infection.
• Are at least 18 years old.
• Weigh at least 50 kg.
• Have documented evidence of virologic failure.
• Have screening HIV genotype done while receiving NNRTI treatment, or within 2 weeks after stopping the treatment.
• Have a viral load (amount of HIV in the blood) of at least 1,000 copies/ml within 45 days prior to Day 1 of study.
• Are willing to use an effective barrier method of birth control during the study. Birth control agents taken by mouth or placed under the skin should not be used as the only method of birth control. If the patient stops taking the study drug, he or she should continue to use birth control for the following 3 months.

Exclusion Criteria

Patients will not be eligible for this study if they:

• Had virologic failure of any treatment containing an HIV protease inhibitor drug.
• Had virologic failure of more than 1 treatment containing an NNRTI drug.
• Have participated in any study using DPC 083.
• Were treated with any experimental NNRTI.
• Have cancer that requires systemic therapy.
• Have a history of blood clotting problems.
• Have attempted suicide or are in danger of hurting themselves.
• Used illegal injection drugs within 6 months of study entry.
• Do not expect to complete 12 months on the study.
• Have not met requirements for HIV genotyping results.
• Have any disease other than HIV infection or other medical problems that the researchers think may interfere with the study.
• Have difficulty swallowing capsules/tablets.
• Have had treatment with immunomodulatory agents such as interferons, interleukins, or thalidomide within 30 days prior to study entry.
• Are using or have used systemic drugs, including glucocorticoids, that suppress the immune system, for over 2 weeks. (Low levels of prednisone are allowed.)
• Have used carbamazepine, phenytoin, or Hypericum perforatum (St. John's wort) within 30 days of beginning study treatment.
• Have had any vaccination within 3 weeks before study screening.
• Have received any experimental therapy within 30 days of beginning study treatment.
• Are pregnant or breast-feeding.
• Abuse alcohol or drugs.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Dupont Applied Biosciences

INDUSTRY

Sponsor Role: lead

Principal Investigators

James Stanford

Role: PRINCIPAL_INVESTIGATOR

Daniel Berger

Role: PRINCIPAL_INVESTIGATOR

Daniel Seekins

Role: PRINCIPAL_INVESTIGATOR

Charles Walworth

Role: PRINCIPAL_INVESTIGATOR

Locations

AIDS Healthcare Foundation

Los Angeles, California, United States

Orange Coast Med Group

Newport Beach, California, United States

Bach and Godofsky

Bradenton, Florida, United States

Saint Josephs Comprehensive Research Institute

Tampa, Florida, United States

Northstar Med Clinic

Chicago, Illinois, United States

Countries

United States

Other Identifiers

DPC 083-203

Identifier Type: -

Identifier Source: secondary_id

314A

Identifier Type: -

Identifier Source: org_study_id